Eli Lilly's experimental lung cancer drug should get value-based pricing - Study

US pharma major Eli Lilly’s (NYSE: LLY) experimental lung cancer drug candidate could be priced between $563 and $1,309 per cycle following regulatory approval, according to an analysis published in JAMA Oncology.

The experimental lung cancer drug, necitumumab, would command a lower price based on the lower level of efficacy it provides, according to the analysis.

Commenting on the findings, a spokeswoman for Eli Lilly said the discussions of pricing for necitumumab are premature, as the therapy has yet to receive regulatory approval.